KAIROS PHARMA, LTD.
NYSE: KAPA (Kairos Pharma, Ltd.)
Last update: yesterday, 5:38PM0.436
-0.02 (-4.60%)
| Previous Close | 0.457 |
| Volume | 33,061 |
| Avg. Volume (3M) | 364,385 |
| Market Cap | 2,042,202 |
| Price / Book | 0.420 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.09 |
| Total Debt/Equity (MRQ) | 4.26% |
| Current Ratio (MRQ) | 6.77 |
| Operating Cash Flow (TTM) | -4.11 M |
| Levered Free Cash Flow (TTM) | -2.55 M |
| Return on Assets (TTM) | -65.65% |
| Return on Equity (TTM) | -110.77% |
AIStockmoo Score
| Value 30% | 0.0 |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Return on Capital info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -5.0 |
| Downtrend over the past year. Far below its 52-week high. info | |
| In a downtrend: the price is below its moving averages, and they are falling. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Holdings' Sentiment info | NA |
| News Mood info | NA |
| Smart Money 20% | -4.0 |
| Institutions net -3.72% of shares in their latest 13F filings: 5 holders increased, 11 decreased (quarter to 30 Sep 2026). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars agree, so the score is strengthened. | |
| Not in score | |
| Earnings per share have mostly fallen. Made a loss in recent years. info | |
| Below its medium-term trend line. info | |
| Price is low against its 52-week average. Down over 5 years. info | |
| Short-term momentum falling. info | |
| Price is near support. info | |
| Final Score | -3.26 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Kairos Pharma, Ltd. | - | - |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| KAPA | 2 M | - | - | 0.420 | -3.3 |
| CYBN | 359 M | - | - | - | 0.0 |
| NRXS | 60 M | - | - | 18.58 | -1.2 |
| CVM | 21 M | - | - | 2.22 | -3.7 |
| NHWK | 20 M | - | - | 0.260 | 0.0 |
| AEON | 10 M | - | - | - | -3.3 |
Select this tab to load the latest available analysis.
|
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 24.29% |
| % Held by Institutions | 3.45% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aptus Capital Advisors, Llc | 30 Sep 2026 | 0 |
| Sevenbridge Financial Group, Llc | 30 Sep 2026 | 0 |
No data within this time range.
Institutions
Institutional ownership: 1.20%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 5 | 14,551 |
| Decreased | 11 | 115,458 |
| New | 2 | 4,680 |
| Sold out | 9 | 89,782 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
| Date | Type | Details |
|---|---|---|
| 05 Nov 2026 | Yahoo Finance |
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
LOS ANGELES, November 05, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for… |
| 03 Nov 2026 | Yahoo Finance |
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
LOS ANGELES, November 03, 2026--Neil Bhowmick, President and CSO of Kairos Pharma, presents on lead candidate ENV-105 and its interim efficacy results at Cancer R&D 2026… |
| 22 Oct 2026 | Yahoo Finance |
CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular… |
| 06 Oct 2026 | Yahoo Finance |
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
LOS ANGELES, October 06, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with… |
| 23 Sep 2026 | Yahoo Finance |
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the… |
| 09 Sep 2026 | Yahoo Finance |
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global… |
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |